Health Care • Biotechnology: Pharmaceutical Preparations
$0.73 ▼ -0.06
(-7.55%)
MKT CAP: $98.3M • VOL: 730.2K
52W L $1 52W H $3
ROARABLE / RQD
D • 47/100
PIOTROSKI
1 / 9
MIST // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$62.1M | -$42.1M | -$61.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$63.1K | -$41.5K | -$59.7K |
| EBITDA (Normalized) | -$61.9M | -$42.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.0M | -$28.8M | -$46.4M |
| Capital Expenditures (CapEx) | $302.0K | $33.0K | — |
| Free Cash Flow (FCF) | -$49.3M | -$28.9M | -$46.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $73.0M | $25.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $41.8M | $13.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MIST.